Marco Campioni

Zug, ZG, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Proposal for a General Outcome-Based Value Attribution Framework for Combination Therapies.

Proposal for a General Outcome-Based Value Attribution Framework for Combination Therapies.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: September 15, 2023

A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.

A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.

Journal: BMC medical research methodology

Published: April 11, 2023

Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review.

Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review.

Journal: BMJ open

Published: July 16, 2020

Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.

Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States.

Journal: Expert review of hematology

Published: April 07, 2020

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials.

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials.

Journal: Leukemia & lymphoma

Published: October 24, 2019

Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting.

Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting.

Journal: Oncology and therapy

Published: July 29, 2019

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States.

Journal: PharmacoEconomics

Published: June 21, 2019

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.

Journal: Journal of medical economics

Published: April 11, 2019

Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology.

Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology.

Journal: PharmacoEconomics

Published: January 06, 2019

Cost per response analysis of strategies for chronic immune thrombocytopenia.

Cost per response analysis of strategies for chronic immune thrombocytopenia.

Journal: The American journal of managed care

Published: July 19, 2018

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma.

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma.

Journal: Journal of managed care & specialty pharmacy

Published: June 29, 2018

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.

Journal: The European journal of health economics : HEPAC : health economics in prevention and care

Published: March 27, 2018

Showing 1-12 of 23

Last Updated: 09/26/2026